Targeting beta-cell preservation in the management of type 2 diabetes
DOI:
https://doi.org/10.15277/bjd.2017.148Keywords:
type 2 diabetes (T2D), beta-cell function, remissionAbstract
Type 2 diabetes (T2D) is widely considered a chronic and progressive disease without cure. As beta-cell function progressively declines over time, blood glucose rises. Current management of T2D involves incremental introduction of dietary and drug therapies to achieve normoglycaemia. However, recent studies have demonstrated remission of T2D following bariatric surgery, very low calorie diet or intensive insulin therapy, raising the possibility that the declining beta-cell function in T2D may be arrested or even reversed. The point at which such interventions are introduced in the course of T2D is key for clinical benefit. Future treatment strategies should be revised to target early beta-cell preservation and thus disease remission. This article reviews the pathogenesis of beta-cell dysfunction and evidence for the clinical benefit of preserving beta-cell function in T2D, and discusses the evidence for beta-cell preservation of current glucose-lowering therapies with particular reference to their effect when initiated at the time of diagnosis of T2D.
References
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–12. https://doi.org/10.1001/jama.281.21.2005
Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 2003;52:1098–103. https://doi.org/10.2337/diabetes.52.5.1098
Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004;27:2597–602. https://doi.org/10.2337/diacare.27.11.2597
Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506–14. https://doi.org/10.1007/s00125-011-2204-7
National Institute for Health and Care Excellence (NICE). NICE guideline [NG 28]. Type 2 diabetes in adults: management. December 2015.
National Diabetes Audit 2013-2014 and 2014-2015. Report 1: Care Processes and Treatment Targets. Health and Social Care Information Centre. 28 January 2016.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89. https://doi.org/10.1056/NEJMoa0806470
Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773–95. https://doi.org/10.2337/db09-9028
Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997;100:1166–73. https://doi.org/10.1172/JCI119628
Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787–94. https://doi.org/10.1172/JCI7231
Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008;51:1781–9. https://doi.org/10.1007/s00125-008-1116-7
Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009;373:2215–21. https://doi.org/10.1016/S0140-6736(09)60619-X
Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004;53(Suppl 3):S16–21.
Brown RJ, Rother KI. Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diabetes 2008;9(3 Pt 2):14–22. https://doi.org/10.1111/j.1399-5448.2007.00272.x
UK Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249–58. https://doi.org/10.2337/diab.44.11.1249
Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009;32(Suppl 2):S151–6. https://doi.org/10.2337/dc09-S301
Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β-cell dedifferentiation as mechanism of diabetic β-cell failure. Cell 2012;150:1223–34. https://doi.org/10.1016/j.cell.2012.07.029
Robertson RP, Zhang HJ, Pyzdrowski KL, Walseth TF. Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. J Clin Invest 1992;90:320–5. https://doi.org/10.1172/JCI115865
Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003;52:581–7. https://doi.org/10.2337/diabetes.52.3.581
Gleason CE, Gonzalez M, Harmon JS, Robertson RP. Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. Am J Physiol Endocrinol Metab 2000;279:E997–1002.
Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 1994;93:870–6. https://doi.org/10.1172/JCI117042
Cnop M, Hannaert JC, Hoorens A, Eizirik DL, Pipeleers DG. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 2001;50:1771–7. https://doi.org/10.2337/diabetes.50.8.1771
Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontes G. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2010;1801:289–98. https://doi.org/10.1016/j.bbalip.2009.08.006
Hasnain SZ, Prins JB, McGuckin MA. Oxidative and endoplasmic reticulum stress in β-cell dysfunction in diabetes. J Mol Endocrinol 2016;56:R33–R54. https://doi.org/10.1530/JME-15-0232
Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997;46:1733–42. https://doi.org/10.2337/diab.46.11.1733
Robertson RP. Oxidative stress and impaired insulin secretion in type 2 diabetes. Curr Opin Pharmacol 2006;6:615–19. https://doi.org/10.1016/j.coph.2006.09.002
Del Guerra S, Lupi R, Marselli L, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 2005;54:727–35. https://doi.org/10.2337/diabetes.54.3.727
Paolisso G, Giugliano D, Pizza G, et al. Glutathione infusion potentiates glucose-induced insulin secretion in aged patients with impaired glucose tolerance. Diabetes Care 1992;15:1–7. https://doi.org/10.2337/diacare.15.1.1
Masha A, Brocato L, Dinatale S, Mascia C, Biasi F, Martina V. N-acetylcysteine is able to reduce the oxidation status and the endothelial activation after a high-glucose content meal in patients with type 2 diabetes mellitus. J Endocrinol Invest 2009;32:352–6. https://doi.org/10.1007/BF03345726
Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocrinol Rev 2008;29:42–61. https://doi.org/10.1210/er.2007-0015
Laybutt DR, Preston AM, Akerfeldt MC, et al. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia 2007;50:752–63. https://doi.org/10.1007/s00125-006-0590-z
Marchetti P, Bugliani M, Lupi R, et al. The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 2007;50:2486–94. https://doi.org/10.1007/s00125-007-0816-8
Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. Islet-associated macrophages in type 2 diabetes. Diabetologia 2009;52:1686–8. https://doi.org/10.1007/s00125-009-1410-z
Boni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008;93:4065–74. https://doi.org/10.1210/jc.2008-0396
Eldor R, Yeffet A, Baum K, et al. Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci USA 2006;103:5072–7. https://doi.org/10.1073/pnas.0508166103
Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110:851–60. https://doi.org/10.1172/JCI15318
Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517–26. https://doi.org/10.1097/PCC.0b013e318198b139
Jurgens CA, Toukatly MN, Fligner CL, et al. Beta-cell loss and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 2011;178:2632–40. https://doi.org/10.1016/j.ajpath.2011.02.036
Montane J, Klimek-Abercrombie A, Potter KJ, Westwell-Roper C, Bruce Verchere C. Metabolic stress, IAPP and islet amyloid. Diabetes Obes Metab 2012;14(Suppl 3):68–77. https://doi.org/10.1111/j.1463-1326.2012.01657.x
Rorsman P, Eliasson L, Renström E, Gromada J, Barg S, Göpel S. The cell physiology of biphasic insulin secretion. Physiology 2000;15:72–7.
Ratzmann KP, Schulz B, Witt S, Heinke P, Ziegler M. Changes of early insulin responses to glucose in obese subjects with normal and impaired carbohydrate tolerance. Endokrinologie 1981;78:89–98.
Ryan EA, Imes S, Liu D, et al. Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes 1995;44:506–12. https://doi.org/10.2337/diab.44.5.506
Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989;321:337–43. https://doi.org/10.1056/NEJM198908103210601
Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233–40. https://doi.org/10.2337/diacare.22.2.233
Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999;48:99–105. https://doi.org/10.2337/diabetes.48.1.99
Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992;15:442–55. https://doi.org/10.2337/diacare.15.3.442
Temple RC, Clark PM, Nagi DK, Schneider AE, Yudkin JS, Hales CN. Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol 1990;32:689–93. https://doi.org/10.1111/j.1365-2265.1990.tb00915.x
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102–10. https://doi.org/10.2337/diabetes. 52.1.102
Sourij H, Saely CH, Schmid F, et al. Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographied coronary patients. Eur Heart J 2010;31:1583–90. https://doi.org/10.1093/eurheartj/ehq099
Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381–6. https://doi.org/10.2337/dc08-1671
Raz I, Ceriello A, Wilson PW, et al. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. Diabetes Care 2011;34:1511–3. https://doi.org/10.2337/dc10-2375
NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463–76. https://doi.org/10.1056/NEJMoa1001122
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486–94. https://doi.org/10.1001/jama.290.4.486
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53.
Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319–28. https://doi.org/10.1056/NEJMoa1203858
Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–91. https://doi.org/10.1056/NEJMoa0706245
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129–39. https://doi.org/10.1056/NEJMoa0808431
Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545–59. https://doi.org/10.1056/NEJMoa0802743
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72. https://doi.org/10.1056/NEJMoa0802987
Gerstein HC, Miller ME, Ismail-Beigi F, et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 2014;384:1936–41. https://doi.org/10.1016/S0140-6736(14)60611-5
Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545–59. https://doi.org/10.1056/NEJMoa0802743
ACCORD Study Group. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care 2016;39:701–08. https://doi.org/10.2337/dc15-2283
Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371:1392–406. https://doi.org/10.1056/NEJMoa1407963
Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985;61:917–25. https://doi.org/10.1210/jcem-61-5-917
Jackness C, Karmally W, Febres G, et al. Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and beta-cell function in type 2 diabetic patients. Diabetes 2013; 62:3027–32. https://doi.org/10.2337/db12-1762
Malandrucco I, Pasqualetti P, Giordani I, et al. Very-low-calorie diet: a quick therapeutic tool to improve beta cell function in morbidly obese patients with type 2 diabetes. Am J Clin Nutr 2012;95:609–13. https://doi.org/10.3945/ajcn.111.023697
Jazet IM, de Craen AJ, van Schie EM, Meinders AE. Sustained beneficial metabolic effects 18 months after a 30-day very low calorie diet in severely obese, insulin-treated patients with type 2 diabetes. Diabetes Res Clin Pract 2007;77:70–6. https://doi.org/10.1016/j.diabres.2006.10.019
Wing RR, Marcus MD, Salata R, Epstein LH, Miaskiewicz S, Blair EH. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. Arch Intern Med 1991;151:1334–40. https://doi.org/10.1001/archinte.1991.00400070100012
Dhindsa P, Scott AR, Donnelly R. Metabolic and cardiovascular effects of very-low-calorie diet therapy in obese patients with type 2 diabetes in secondary failure: outcomes after 1 year. Diabet Med 2003;20:319–24. https://doi.org/10.1046/j.1464-5491.2003.00937.x
Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration type 2 diabetes. Diabet Med 2015;32:1149–55. https://doi.org/10.1111/dme.12722
Steven S, Hollingsworth KG, Al-Mrabeh A, et al. Very-low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiologic changes in responders and nonresponders. Diabetes Care 2016;39:808–15. https://doi.org/10.2337/dc15-1942
Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006(3):Cd002968.
Michishita R, Shono N, Kasahara T, Tsuruta T. Effects of low intensity exercise therapy on early phase insulin secretion in overweight subjects with impaired glucose tolerance and type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;82:291–7. https://doi.org/10.1016/j.diabres.2008.08.013
Solomon TPJ, Haus JM, Kelly KR, Rocco M, Kashyap SR, Kirwan JP. Improved pancreatic β-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide. Diabetes Care 2010;33:1561–6. https://doi.org/10.2337/dc09-2021
Dela F, von Linstow ME, Mikines KJ, Galbo H. Physical training may enhance β-cell function in type 2 diabetes. Am J Physiol Endocrinol Metab 2004;287:E1024–31. https://doi.org/10.1152/ajpendo.00056.2004
Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002;51(Suppl 1):S134–7.
Patane G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2000;49:735–40. https://doi.org/10.2337/diabetes.49.5.735
Kahn SE, Lachin JM, Zinman B, et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes 2011;60:1552–60. https://doi.org/10.2337/db10-1392
Sun W, Zeng C, Liao L, Chen J, Wang Y. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obese. Curr Med Res Opin 2016;32:1389–96. https://doi.org/10.1080/03007995.2016.1176013
Lang V, Youssef N, Light PE. The molecular genetics of sulfonylurea receptors in the pathogenesis and treatment of insulin secretory disorders and type 2 diabetes. Curr Diabetes Rep 2011;11:543–51. https://doi.org/10.1007/s11892-011-0233-8
Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002;25:1607–11. https://doi.org/10.2337/diacare.25.9.1607
Ligtenberg JJ, Reitsma WD, van Haeften TW. Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus. Horm Metab Res 2001;33:361–4. https://doi.org/10.1055/s-2001-15411
Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501–06. https://doi.org/10.1210/jc.2004-0699
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–43. https://doi.org/10.1056/NEJMoa066224
Dubois M, Pattou F, Kerr-Conte J, et al. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in normal human pancreatic islet cells. Diabetologia 2000;43:1165–9. https://doi.org/10.1007/s001250051508
Gastaldelli A, Miyazaki Y, Pettiti M, et al. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:806–12. https://doi.org/10.1210/jc.2005-1159
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106–18. https://doi.org/10.1056/NEJMra041001
Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004;286:E560–7.
Kim HI, Cha JY, Kim SY, et al. Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells. Diabetes 2002;51:676–85. https://doi.org/10.2337/diabetes.51.3.676
Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292:E871–83.
Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 2004;27:2585–9. https://doi.org/10.2337/diacare.27.11.2585
Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796–803. https://doi.org/10.2337/diabetes.51.9.2796
Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096–105. https://doi.org/10.1016/S0140-6736(06)69420-8
DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104–15. https://doi.org/10.1056/NEJMoa1010949
Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517–22. https://doi.org/10.2337/diabetes.55.02.06.db05-1066
Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093–104. https://doi.org/10.1007/s00125-005-1751-1
Chao EC, Henry RR. SGLT2 inhibition – a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551–9.https://doi.org/10.1038/nrd3180
Shimo N, Matsuoka TA, Miyatsuka T, et al. Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key beta-cell factors under diabetic conditions. Biochem Biophys Res Commun 2015;467:948–54. https://doi.org/10.1016/j.bbrc.2015.10.038
Okauchi S, Shimoda M, Obata A, et al. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in obese type 2 diabetic db/db mice. Biochem Biophys Res Commun 2016;470:772–82. https://doi.org/10.1016/j.bbrc.2015.10.109
Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232–8. https://doi.org/10.2337/dc11-1926
Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512–17. https://doi.org/10.1038/nm.3828
Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509–14. https://doi.org/10.1172/JCI70704
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301–07. https://doi.org/10.1172/JCI116186
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–705. https://doi.org/10.1016/S0140-6736(06)69705-5
Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987;84:3434–8. https://doi.org/10.1073/pnas.84.10.3434
Holz GG 4th, Kiihtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37). Nature 1993;361:362–5. https://doi.org/10.1038/361362a0
Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270–6. https://doi.org/10.2337/diabetes.48.12.2270
Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149–58. https://doi.org/10.1210/en.2003-0323
Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008;25:152–6. https://doi.org/10.1111/j.1464-5491.2007.02333.x
Derosa G, Franzetti IG, Querci F, et al. Exenatide plus metformin compared with metformin alone on beta-cell function in patients with type 2 diabetes. Diabet Med 2012;29:1515–23. https://doi.org/10.1111/j.1464-5491.2012.03699.x
Derosa G, Carbone A, D'Angelo A, et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and beta-cell function. Expert Opin Pharmacother 2012;13:2433–42. https://doi.org/10.1517/14656566.2012.730519
Ohkura T, Fujioka Y, Sumi K, et al. Sitagliptin improves the impaired acute insulin response during a meal tolerance test in Japanese patients with type 2 diabetes mellitus: a small-scale real-world study. Diabetes Ther 2014;5:285–97. https://doi.org/10.1007/s13300-014-0071-1
Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270–8. https://doi.org/10.2337/dc14-0893
Kimura T, Kaneto H, Shimoda M, et al. Protective effects of pioglitazone and/or liraglutide on pancreatic beta-cells in db/db mice: comparison of their effects between in an early and advanced stage of diabetes. Mol Cell Endocrinol 2015;400:78–89. https://doi.org/10.1016/j.mce.2014.11.018
Ross SA, Ballantine J. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes. Curr Med Res Opin 2013;29:1617–26. https://doi.org/10.1185/03007995.2013.837817
Bunck MC, Cornér A, Eliasson B, et al. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2041–7. https://doi.org/10.2337/dc11-0291
Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753–60. https://doi.org/10.1016/S0140-6736(08)60762-X
Xu W, Li YB, Deng WP, Hao YT, Weng JP. Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. Chinese Med J 2009;122:2554–9.
Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008;31:1927–32. https://doi.org/10.2337/dc08-0075
Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013;1:28–34. https://doi.org/10.1016/S2213-8587(13)70006-8
Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010;12:65–71. https://doi.org/10.1111/j.1463-1326.2009.01129.x
Park S, Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 2003; 19:124–30. https://doi.org/10.1002/dmrr.343
Retnakaran R, Zinman B. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on beta-cell function. Diabetes Obes Metab 2012;14(Suppl 3):161–6. https://doi.org/10.1111/j.1463-1326.2012.01658.x
Chen H, Ren A, Hu S, Mo W, Xin X, Jia W. The significance of tumor necrosis factor-α in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Res Clin Pract 2007;75:327–32. https://doi.org/10.1016/j.diabres.2006.07.001
Bojsen-Moller KN, Dirksen C, Jorgensen NB, et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 2014;63:1725–37. https://doi.org/10.2337/db13-1307
Martinussen C, Bojsen-Moller KN, Dirksen C, et al. Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. Am J Physiol Endocrinol Metab 2015;308:E535–44. https://doi.org/10.1152/ajpendo.00506.2014
Jorgensen NB, Dirksen C, Bojsen-Moller KN, et al. Exaggerated glucagon-like peptide 1 response is important for improved beta-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 2013;62:3044–52. https://doi.org/10.2337/db13-0022
Jiménez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 2013;36:2062–9. https://doi.org/10.2337/dc12-1535
Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683–93. https://doi.org/10.1056/NEJMoa035622
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248–56.e5. https://doi.org/10.1016/j.amjmed.2008.09.041
Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93–102. https://doi.org/10.1007/s11695-012-0802-1
Published
Issue
Section
License
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
